Targeting a protein to improve treatment for triple negative breast cancer
Official title: Characterizing and targeting PRMT5 in autophagy for cancer treatment
Funded at Medical University of South Carolina · NIH-11077676 · Data updated 2026-11-12
This study is looking at a protein called PRMT5 to see how it affects triple negative breast cancer and whether targeting it with new treatments can help improve care for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $345,413 |
| NIH project number | 5R01CA266522-03 |
| Project ID | NIH-11077676 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer who may benefit from novel treatment approaches.
✕Less likely to help
Patients with non-triple negative breast cancer subtypes are unlikely to benefit from this specific research.
What this research studies
This research focuses on understanding the role of a protein called PRMT5 in the progression of triple negative breast cancer (TNBC), a subtype known for its aggressive nature and poor prognosis. The study aims to explore how PRMT5 affects cancer cell behavior and its potential as a target for new therapies. Researchers will investigate the mechanisms by which PRMT5 influences autophagy, a process that can affect cancer cell survival, and evaluate the effectiveness of PRMT5 inhibitors in combination with other treatments. By identifying how TNBC cells respond to these inhibitors, the research seeks to develop more effective treatment strategies for patients.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates for patients with triple negative breast cancer.
How similar studies have gone: Other research has shown promise in targeting PRMT5 in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Medical University of South Carolina
Charleston, United States Active
Researchers
- Principal investigator: Gan, Wenjian — Medical University of South Carolina
- Study coordinator: Gan, Wenjian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.